OncoSec Medical to Host Corporate Update Conference Call on December 9, 2014
December 05 2014 - 06:02AM
Business Wire
OncoSec Medical Inc. (OTCQB: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, will host a
corporate update conference call on Tuesday, December 9, 2014 at 10
AM ET. The call will cover recent milestone achievements and
corporate and clinical development strategies, but will not address
the company’s results of operations or financial condition for a
completed quarterly or annual fiscal period. To participate in the
call, dial toll-free (855) 801-3670 in the U.S. and Canada or (804)
681-3878 outside the U.S. and Canada and enter conference ID
#48289768.
A replay of the conference call will be available 2 hours after
the call’s completion through January 23, 2015. To access this
recording, dial (855) 859-2056 in the U.S. and Canada or (404)
537-3406 outside the U.S. and Canada and enter conference ID
#48289768.
To listen to the conference call, dial in approximately ten
minutes before the scheduled call. An archived replay of the call
will also be available through the investors page at
www.oncosec.com. Invited participants may ask questions during the
conference call. Others may submit questions before the call by
e-mail addressed to investors@oncosec.com. Submitted questions will
be screened for appropriateness and general interest. Selected
questions received with sufficient notice before the call will be
answered as time permits at the end of the call. For further
information, contact OncoSec's Investor Relations
department by phone at (855) 662-6732 or by email
at investors@oncosec.com
About OncoSec Medical
OncoSec Medical Inc. is a biopharmaceutical company developing
its investigational ImmunoPulse intratumoral cancer immunotherapy.
OncoSec Medical's core technology is designed to
enhance the local delivery and uptake of DNA IL-12 and
other DNA-based immune-targeting agents. Clinical studies of
ImmunoPulse have demonstrated an acceptable safety profile and
preliminary evidence of anti-tumor activity in the treatment of
various skin cancers, as well as the potential to initiate a
systemic immune response without the systemic toxicities associated
with other treatments. OncoSec's lead program evaluating
ImmunoPulse for the treatment of metastatic melanoma is currently
in Phase 2 development, and is being conducted in collaboration
with several prominent academic medical centers. As the company
continues to evaluate ImmunoPulse in its current indications, it is
also focused on identifying and developing new immune-targeting
agents, investigating additional tumor indications, and evaluating
combination-based immunotherapy approaches. For more information,
please visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
Investor Relations:OncoSec Medical Inc.Jordyn Kopin,
855-662-6732investors@oncosec.comorPublic Relations:Dian Griesel
Int’l.Laura Radocaj, 212-825-3210lradocaj@dgicomm.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Feb 2024 to Mar 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2023 to Mar 2024